<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A phase-I/II trial was initiated to study the effect of rhGM-CSF in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> who were not eligible for other kinds of therapy, rhGM-CSF was given to 9 patients in doses of 15 micrograms/m2-150 micrograms/m2 as an intravenous 8-h infusion for a cycle of 7 days followed by an interval of 14 days and a second 7-day treatment course </plain></SENT>
<SENT sid="1" pm="."><plain>A dose-dependent increase in the leukocyte count was observed in 7 out of 9 patients </plain></SENT>
<SENT sid="2" pm="."><plain>No change in reticulocyte numbers was seen and only 1 patient experienced an increase in platelet count </plain></SENT>
<SENT sid="3" pm="."><plain>Toxicity mainly consisted of mild local <z:mp ids='MP_0010140'>phlebitis</z:mp> at the site of infusion and sternal pain after bolus injection </plain></SENT>
</text></document>